Background. Vaccines are not free from side effects, most of which are generally mild, whilst others can occasionally be more serious and even life-threatening. This study was hence aimed to provide an updated analysis of voluntarily reported mild adverse reactions after COVID-19 vaccination in Italy. Methods. Data on mild adverse reactions after vaccination with Pfizer Comirnaty, Moderna COVID-19 Vaccine and AstraZeneca Vaxzevria were retrieved with an electronic search in the public Italian Medicines Agency (AIFA) database of Adverse Drug Reactions up to March 31, 2021. Frequency of mild adverse events was compared among the three vaccines. Results. With respect to the cumulative number of adverse reactions, fever was the most frequently reported side effect of all vaccines (13.2%), followed by headache (10.3%), myalgia (8.7%), pain at injection site (8.3%), arthralgia (7.9%), tiredness/fatigue (6.2%). Headache, myalgia, pain at injection site, arthralgia, tiredness/fatigue, chills and lymphadenopathy were higher after Pfizer Comirnaty than Moderna COVID-19 Vaccine whilst fever, malaise and vomiting were lower (all p<0.001). Pain at injection site, tiredness/fatigue, lymphadenopathy and malaise were higher after Pfizer Comirnaty than AstraZeneca Vaxzevria (all p<0.001),, whilst fever (p<0.001), headache (p<0.001), nausea (p=0.003) and vomiting (p<0.001) were lower. Pain at injection site, lymphadenopathy and malaise were more frequently reported after Moderna COVID-19 Vaccine than AstraZeneca Vaxzevria, whilst headache, myalgia, arthralgia, tiredness/fatigue and chills were lower (all p<0.001). Conclusion. This analysis of vaccine-specific mild adverse reactions may help guide decisions about individual preferences, when appropriate, towards administration of one type of vaccine instead than another, especially among those with (or at high risk of) malignancy.